IL301039A - Treatment of parkinson's disease - Google Patents

Treatment of parkinson's disease

Info

Publication number
IL301039A
IL301039A IL301039A IL30103923A IL301039A IL 301039 A IL301039 A IL 301039A IL 301039 A IL301039 A IL 301039A IL 30103923 A IL30103923 A IL 30103923A IL 301039 A IL301039 A IL 301039A
Authority
IL
Israel
Prior art keywords
subject
prasinezumab
parkinson
disease
weeks
Prior art date
Application number
IL301039A
Other languages
English (en)
Hebrew (he)
Original Assignee
Prothena Biosciences Ltd
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Hoffmann La Roche filed Critical Prothena Biosciences Ltd
Publication of IL301039A publication Critical patent/IL301039A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL301039A 2020-09-10 2021-09-10 Treatment of parkinson's disease IL301039A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063076916P 2020-09-10 2020-09-10
US202063076915P 2020-09-10 2020-09-10
US202063076913P 2020-09-10 2020-09-10
US202163158191P 2021-03-08 2021-03-08
PCT/US2021/049785 WO2022056209A1 (en) 2020-09-10 2021-09-10 Treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
IL301039A true IL301039A (en) 2023-05-01

Family

ID=80629905

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301039A IL301039A (en) 2020-09-10 2021-09-10 Treatment of parkinson's disease

Country Status (10)

Country Link
US (2) US12084491B2 (enExample)
EP (1) EP4211162A4 (enExample)
JP (1) JP2023541048A (enExample)
KR (1) KR20230086674A (enExample)
AU (1) AU2021338781A1 (enExample)
CR (1) CR20230121A (enExample)
IL (1) IL301039A (enExample)
MX (1) MX2023002851A (enExample)
TW (1) TW202227131A (enExample)
WO (1) WO2022056209A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20240279316A1 (en) * 2022-12-29 2024-08-22 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
CN117409969B (zh) * 2023-11-13 2026-04-03 深圳市臻络科技有限公司 帕金森病运动功能评估方法、装置及电子设备

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7981058B2 (en) 2004-03-12 2011-07-19 The Trustees Of Dartmouth College Intelligent wearable monitor systems and methods
US20060122472A1 (en) 2004-09-28 2006-06-08 Pullman Seth L System and method for clinically assessing motor function
US8702629B2 (en) 2005-03-17 2014-04-22 Great Lakes Neuro Technologies Inc. Movement disorder recovery system and method for continuous monitoring
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
JP5251270B2 (ja) 2008-06-04 2013-07-31 三菱化学株式会社 パーキンソン病の評価装置
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
US20100076348A1 (en) 2008-09-23 2010-03-25 Apdm, Inc Complete integrated system for continuous monitoring and analysis of movement disorders
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
CN101963919A (zh) 2009-07-24 2011-02-02 鸿富锦精密工业（深圳）有限公司 进程管理系统
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9924899B2 (en) 2013-09-09 2018-03-27 Alexis Pracar Intelligent progression monitoring, tracking, and management of parkinson's disease
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
JP6595490B2 (ja) 2014-02-04 2019-10-23 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター 身体固定センサを使用してパーキンソン病の診断または予後を提供する方法およびシステム
US20180126158A1 (en) 2016-08-22 2018-05-10 Lyriq, Llc Systems and Methods for Functional Restoration and Rehabilitation of Posture, Gait and Movement
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
EP3833435B1 (en) 2018-08-09 2025-09-24 F. Hoffmann-La Roche AG Determination of parkinson's disease
KR20230154249A (ko) 2021-03-08 2023-11-07 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료

Also Published As

Publication number Publication date
US12084491B2 (en) 2024-09-10
US20220098291A1 (en) 2022-03-31
WO2022056209A1 (en) 2022-03-17
TW202227131A (zh) 2022-07-16
US20250188158A1 (en) 2025-06-12
MX2023002851A (es) 2023-03-22
CR20230121A (es) 2023-07-26
EP4211162A4 (en) 2025-04-30
EP4211162A1 (en) 2023-07-19
JP2023541048A (ja) 2023-09-27
AU2021338781A1 (en) 2023-03-30
KR20230086674A (ko) 2023-06-15

Similar Documents

Publication Publication Date Title
US12084491B2 (en) Treatment of Parkinson's disease
US9351961B2 (en) Method of treating multiple sclerosis
CZ29723U1 (cs) Nízkofrekvenční terapie s glatiramer acetátem
AU2023208107B2 (en) Composition comprising an anti-Αβ protofibril antibody and a beta- secretase BACE1 inhibitor for the treatment of Alzheimer's disease
CN1711101A (zh) 孤独症及相似障碍的治疗
AU2021200093A1 (en) Treatment and prevention of alzheimer's disease (ad)
WO2023034115A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
US11351229B2 (en) Combination therapies for treating infantile spasms and other treatment resistant epilepsies
RU2848183C1 (ru) Лечение болезни паркинсона
US10071077B2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
CN116802208A (zh) 帕金森氏病的治疗
AU2023403257A1 (en) Methods for treating neurodegenerative disorders with tramiprosate
Seewann et al. Practical management of multiple sclerosis
Yakushiji et al. Interferon ß-responsive inclusion body myositis in a hepatitis C virus carrier
WO2011043788A2 (en) Daptomycin for multiple sclerosis